Information Provided By: 
Fly News Breaks for September 7, 2017
ENDP, COLL
Sep 7, 2017 | 05:55 EDT
Jefferies analyst David Steinberg says shares of Collegium Pharmaceutical (COLL) have been weak despite the acceleration of Xtampza prescription trends since June. With the company likely on track to exceed expectations, the valuation at current share levels "looks very attractive," Steinberg tells investors in a research note. He also believes the benefit from Endo's (ENDP) Opana market withdrawal may start kicking in soon. The analyst keeps a Buy rating on Collegium with a $15 price target.
News For COLL;ENDP From the Last 2 Days
There are no results for your query COLL;ENDP
